Friesen E - Search Results

1

Determinants of success and failure of EMLA.

Lander J, Hodgins M, Nazarali S, McTavish J, Ouellette J, Friesen E. Lander J, et al. Among authors: friesen e. Pain. 1996 Jan;64(1):89-97. doi: 10.1016/0304-3959(95)00100-X. Pain. 1996. PMID: 8867250 Clinical Trial.

2

Evaluation of a new topical anesthetic agent: a pilot study.

Lander J, Nazarali S, Hodgins M, Friesen E, McTavish J, Ouellette J, Abel R. Lander J, et al. Among authors: friesen e. Nurs Res. 1996 Jan-Feb;45(1):50-3. doi: 10.1097/00006199-199601000-00009. Nurs Res. 1996. PMID: 8570423 Clinical Trial. No abstract available.

3

Clinical presentation and management of acute 2,4-D oral ingestion.

Friesen EG, Jones GR, Vaughan D. Friesen EG, et al. Drug Saf. 1990 Mar-Apr;5(2):155-9. doi: 10.2165/00002018-199005020-00006. Drug Saf. 1990. PMID: 2322426

4

Serum theophylline profile with once-daily theophylline (Uniphyl) following conversion from intravenous theophylline in adult asthmatic patients.

Fradette M, Babich M, Friesen EG, Archibald JS, Babul N. Fradette M, et al. Among authors: friesen eg. Clin Ther. 1994 Mar-Apr;16(2):160-8. Clin Ther. 1994. PMID: 8062311 Clinical Trial.

5

Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.

Palylyk-Colwell E, Jamali F, Dryden W, Friesen E, Koven S, Mohamed I, Osmond B, Alessi-Severini S, Sheldon L, Sheldon R, Tam Y, Tsuyuki R, Zhanel G. Palylyk-Colwell E, et al. Among authors: friesen e. J Pharm Pharm Sci. 1998 Jan-Apr;1(1):2-7. J Pharm Pharm Sci. 1998. PMID: 10942966 Free article. No abstract available.

6

Spironolactone-induced agranulocytosis.

Jivraj KT, Noseworthy TW, Friesen EG, Shustack AS, Konopad EM, Johnston RG. Jivraj KT, et al. Among authors: friesen eg. Drug Intell Clin Pharm. 1987 Dec;21(12):974-5. doi: 10.1177/106002808702101208. Drug Intell Clin Pharm. 1987. PMID: 3428161

7

In vitro recovery of carbamazepine from ensure.

Kassam RM, Friesen E, Locock RA. Kassam RM, et al. Among authors: friesen e. JPEN J Parenter Enteral Nutr. 1989 May-Jun;13(3):272-6. doi: 10.1177/0148607189013003272. JPEN J Parenter Enteral Nutr. 1989. PMID: 2503637

8

Reassessing the relevance of pharmacoeconomic analyses in formulary decisions.

Johnson JA, Friesen E. Johnson JA, et al. Among authors: friesen e. Pharmacoeconomics. 1998 May;13(5 Pt 1):479-85. doi: 10.2165/00019053-199813050-00001. Pharmacoeconomics. 1998. PMID: 10180747 Review. No abstract available.

9

Containing cefoxitin costs through a program to curtail use in surgical prophylaxis.

Taylor G, Blondel-Hill E, Kibsey P, Friesen E, Tisdell R, Vaudry W. Taylor G, et al. Among authors: friesen e. Can J Infect Dis. 1993 Sep;4(5):275-8. doi: 10.1155/1993/875916. Can J Infect Dis. 1993. PMID: 22346462 Free PMC article.

10

Theophylline loading dose in obese patients.

Visram N, Friesen EG, Jamali F. Visram N, et al. Among authors: friesen eg. Clin Pharm. 1987 Mar;6(3):188-9. Clin Pharm. 1987. PMID: 3665374 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

81 results

Search Page